Svetlana Lucas, Ph.d.

Biography

Svetlana joined Tizona Therapeutics as Vice President of Business Development in July of 2015. In her role, she is responsible for the company’s business development strategy and transactions. Prior to Tizona, Svetlana was Executive Director, Head of Oncology & Inflammation External R&D at Amgen, where she oversaw business development activities, including Amgen’s strategic cancer immunotherapy research collaboration and licensing agreement with Kite Pharma, and collaborated with Amgen Ventures on several investments in oncology and inflammation. Svetlana joined Amgen following the acquisition of Onyx Pharmaceuticals, Inc. During her time at Onyx, she spearheaded the company’s oncology partnering strategy and was instrumental in search, evaluation and due diligence of new opportunities. Prior to Onyx, she held positions of increasing responsibility in strategy, business development and strategic marketing at Amgen, as well as several medium size biotech companies in the Bay Area. She began her career as a strategy consultant in the Life Sciences practice of McKinsey & Company. Svetlana received her Ph.D. in Molecular Biology & Biochemistry from Caltech, where she worked with Ray Deshaies, founder of Proteolix and Cleave Biosciences, on the cell cycle regulation and ubiquitin-proteasome pathway in human cells.

Research Interest

Svetlana joined Tizona Therapeutics as Vice President of Business Development in July of 2015. In her role, she is responsible for the company’s business development strategy and transactions. Prior to Tizona, Svetlana was Executive Director, Head of Oncology & Inflammation External R&D at Amgen, where she oversaw business development activities, including Amgen’s strategic cancer immunotherapy research collaboration and licensing agreement with Kite Pharma, and collaborated with Amgen Ventures on several investments in oncology and inflammation. Svetlana joined Amgen following the acquisition of Onyx Pharmaceuticals, Inc. During her time at Onyx, she spearheaded the company’s oncology partnering strategy and was instrumental in search, evaluation and due diligence of new opportunities. Prior to Onyx, she held positions of increasing responsibility in strategy, business development and strategic marketing at Amgen, as well as several medium size biotech companies in the Bay Area. She began her career as a strategy consultant in the Life Sciences practice of McKinsey & Company. Svetlana received her Ph.D. in Molecular Biology & Biochemistry from Caltech, where she worked with Ray Deshaies, founder of Proteolix and Cleave Biosciences, on the cell cycle regulation and ubiquitin-proteasome pathway in human cells.